Cancer News and Research

Latest Cancer News and Research

AHA urges Americans to wear red to raise awareness about women and heart health

On the first Friday of February, The American Heart Association (AHA) urges Americans to wear red to raise awareness about women and heart health. According to the AHA, nearly half of American women do not know that heart disease is their No. 1 killer, and less than half know the best blood pressure and cholesterol levels for cardiovascular health.

24 Jan 2012

KSU professor turns to nutrition to tackle prostate cancer

A Kansas State University professor is turning to nutrition to tackle prostate cancer. Brian Lindshield, assistant professor of human nutrition, is helping men make more informed diet decisions by studying foods and dietary supplements that may reduce the risk of prostate cancer. Prostate cancer is one of the most common forms of cancer among men in the United States.

24 Jan 2012

Researchers evaluate colonoscopy quality performance and reporting in daily practice

Researchers in the Netherlands assessed the quality of colonoscopy reporting in daily clinical practice and evaluated the quality of colonoscopy performance. They found that colonoscopy reporting varied significantly in clinical practice.

24 Jan 2012

Power3, Amarantus sign license agreement for NuroPro Blood Test for Parkinson's

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein being developed for the treatment of Parkinson's Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. for the NuroPro Blood Test as it relates to Parkinson's disease diagnosis.

24 Jan 2012

miR-375 can predict life threatening head and neck cancers

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have found a biomarker in head and neck cancers that can predict whether a patient's tumor will be life threatening.

24 Jan 2012

MMRF earns Charity Navigator's 4-star rating

The Multiple Myeloma Research Foundation (MMRF) announced today that Charity Navigator, America's premier independent evaluator of charitable organizations, has awarded the MMRF with its 4-star rating, the highest rating possible, for the ninth consecutive year - demonstrating exceptional fiscal responsibility in the MMRF's efforts to bring patients the next generation of treatments and find a cure for multiple myeloma.

24 Jan 2012

New book explores how patients and doctors deal with cancer

Jonathan Waxman, a professor of oncology, was inspired to write a book by his conversations with his patients. Here, he gained insight into his patients' fears, hopes, and the impact the disease has on their lives. In The Elephant in the Room, Waxman explores the relationship of patient and specialist, how both sides deal with cancer, their interactions, and what doctors actually mean when talking to their patients.

24 Jan 2012

Chromosome aberrations happen in pairs when it comes to cancer

A healthy genome is characterized by 23 pairs of chromosomes, and even a small change in this structure - such as an extra copy of a single chromosome - can lead to severe physical impairment. So it's no surprise that when it comes to cancer, chromosomal structure is frequently a contributing factor, says Prof. Ron Shamir of the Blavatnik School of Computer Science at Tel Aviv University.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

CQA derivatives in mate tea kill human colon cancer cells

Could preventing colon cancer be as simple as developing a taste for yerba mate tea? In a recent University of Illinois study, scientists showed that human colon cancer cells die when they are exposed to the approximate number of bioactive compounds present in one cup of this brew, which has long been consumed in South America for its medicinal properties.

24 Jan 2012

OPKO acquires two new prostate cancer biomarkers from Arctic Partners

OPKO Health, Inc. today announced the acquisition of an exclusive license from Arctic Partners Ab Oy for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%.

24 Jan 2012

Elevated blood lead levels put smokers at higher risk for renal cell carcinoma

Higher than normal levels of lead in the blood may signal a risk two times higher than average of developing renal cell carcinoma in smokers, according to medical researchers.

24 Jan 2012

Dutasteride delays prostate cancer progression in men

For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network.

24 Jan 2012

Targeting a single protein can help fight both breast cancers and leukemias

Targeting a single protein can help fight both breast cancers and leukemias, according to two reports published online on January 23 in the Journal of Experimental Medicine.

24 Jan 2012

Scientists reveal structure of cellular protein degradation machinery

Defective proteins that are not disposed of by the body can cause diseases such as Alzheimer's or Parkinson's. Scientists at the Max Planck Institute (MPI) of Biochemistry recently succeeded in revealing the structure of the cellular protein degradation machinery (26S proteasome) by combining different methods of structural biology.

24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

Researchers uncover 13 novel genetic loci linked with onset of menopause

An international team of researchers from the Boston University Schools of Public Health and Medicine and other institutions has uncovered 13 genetic loci, linked to immune function and DNA repair, that are factors in the age of onset of menopause.

24 Jan 2012

Guided Therapeutics seeks CE Mark approval for LuViva Advanced Cervical Scan

Guided Therapeutics, Inc. today announced that it has submitted the application for CE Mark approval for LuViva Advanced Cervical Scan. The CE Mark is required to market LuViva in the 27 nations that comprise the European Union (EU).

23 Jan 2012

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

23 Jan 2012

EntreMed announces $10 million in financing from strategic accredited investors

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has secured $10 million in financing with strategic accredited investors, including IDG-Accel China Growth Fund II L.P., Emerging Technology Partners, LLC, and Dr. Tak W. Mak, Director of The Campbell Family Institute for Cancer Research.

23 Jan 2012